Peroxisome Proliferator-Activated Receptor γ Is a Target for Halogenated Analogs of Bisphenol A
Anne Riu, Marina Grimaldi, Albane Le Maire, Gilbert Bey, Abdelhay Boulahtouf, Elisabeth Perdu, Daniel Zalko, William Bourguet, Patrick Balaguer

To cite this version:
Anne Riu, Marina Grimaldi, Albane Le Maire, Gilbert Bey, Abdelhay Boulahtouf, et al.. Peroxisome Proliferator-Activated Receptor γ Is a Target for Halogenated Analogs of Bisphenol A. Environmental Health Perspectives, National Institute of Environmental Health Sciences, 2011, 119 (9), pp.1227-1232. 10.1289/ehp.1003328 . hal-02652231

HAL Id: hal-02652231
https://hal.inrae.fr/hal-02652231
Submitted on 29 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Peroxisome Proliferator-Activated Receptor γ Is a Target for Halogenated Analogs of Bisphenol A

Anne Riu,1 Marina Grimaldi,2,3,4,5 Albane le Maire,6,7 Gilbert Bey,9 Kevin Phillips,9 Abdelhay Boulahtouf,2,3,4,5 Elisabeth Perdu,1 Daniel Zalko,1 William Bourguet,6,7 and Patrick Balague2,3,4,5

1INRA (National Institute of Agronomic Research), UMR 1089 Xénobiotiques, Toulouse, France; 2IRCM (Institut de Recherche en Cancérologie de Montpellier), Montpellier, France; 3INSERM (Institut National de la Santé et de la Recherche Médicale) U896, Montpellier, France; 4Université Montpellier 1, Montpellier, France; 5CRLC (Centre Régional de Lutte contre le Cancer) Val d’Aurelle Paul Lamarque, Montpellier, France; 6INSERM U1054, Centre de Biochimie Structurale, Montpellier, France; 7CNRS (Centre National de la Recherche Scientifique) UMR5048, Universités Montpellier 1 & 2, Montpellier, France; 8NovAliX, Illkirch, France; 9Methodist Hospital Research Institute, Houston, Texas, USA

BACKGROUND: The occurrence of halogenated analogs of the xenooestrogen bisphenol A (BPA) has been recently demonstrated both in environmental and human samples. These analogs include brominated [e.g., tetrabromobisphenol A (TBBPA)] and chlorinated [e.g., tetrachlorobisphenol A (TCBPA)] bisphenols, which are both flame retardants. Because of their structural homology with BPA, such chemicals are candidate endocrine disruptors. However, their possible target(s) within the nuclear hormone receptor superfamily has remained unknown.

OBJECTIVES: We investigated whether BPA and its halogenated analogs could be ligands of estrogen receptors (ERs) and peroxisome proliferator–activated receptors (PPARs) and act as endocrine-disrupting chemicals.

METHODS: We studied the activity of compounds using reporter cell lines expressing ERs and PPARs. We measured the binding affinities to PPARγ by competitive binding assays with [3H]-rosiglitazone and investigated the impact of TBBPA and TCBPA on adipocyte differentiation using NIH3T3-L1 cells. Finally, we determined the binding mode of halogenated BPAs to PPARγ by X-ray crystallography.

RESULTS: We observed that TBBPA and TCBPA are human, zebrafish, and Xenopus PPARγ ligands and determined the mechanism by which these chemicals bind to and activate PPARγ. We also found evidence that activation of ERs, ERα, and PPARγ depends on the degree of halogenation in BPA analogs. We observed that the bulkier brominated BPA analogs, the greater their capability to activate PPARγ and the weaker their estrogenic potential.

CONCLUSIONS: Our results strongly suggest that polyhalogenated bisphenols could function as obesogens by acting as agonists to disrupt physiological functions regulated by human or animal PPARγ.


Bisphenols form a large family of chemicals that are used mainly to produce polycarbonates and epoxy resins. By far, the most widely used bisphenol (> 3 million tons/year) is bisphenol A (BPA), which is used in the manufacture of items such as plastics, food can linings, dentistry sealants, and thermal paper. BPA (Figure 1) is a model xenooestrogen. Despite possessing only modest estrogenic activity compared with 17β-estradiol (E2), over the last decade BPA has been shown to produce a range of adverse effects in laboratory animals, with major concerns regarding reproductive targets (Richter et al. 2007). More recently, it has been hypothesized that early exposure to BPA could play a role in the onset of obesity and other metabolic syndromes (Rubin and Soto 2009). In this regard, a large body of data about endocrine-disrupting chemicals (EDCs) underlines the importance of exposure during early stages of development, which could result in reproductive defects in adult life (Newbold et al. 2009). Human exposure to BPA has been clearly demonstrated (Calafat et al. 2008). However low-dose effects of BPA and the possible consequences of such exposure are controversial (Vandenbergh et al. 2009; vom Saal and Hughes 2005).

Halogenated derivatives of BPA, which feature bromine or chlorine substituents on the phenolic rings, are used as flame retardants. However, compared with BPA, little information is available regarding the potential endocrine disruption by these compounds. All brominated BPA analogs originate from tetrabromobisphenol A (TBBPA), which is the most-produced brominated flame retardant (> 150,000 tons produced annually) (de Wit et al. 2010). TBBPA (Figure 1) is used to produce fireproof epoxy resins used in the manufacture of computer motherboards and other electronics; and it has been found in environmental samples has been unequivocally demonstrated (Fukazawa et al. 2001). Given the low production level of TCBPA, its presence in the environment most likely originates from the spontaneous chlorination of BPA. Indeed, like many phenolic compounds, BPA is readily chlorinated in aqueous media (Deborde et al. 2004).

The estrogenic activity of BPA exerted through binding to estrogen receptors (ERs) is likely involved in the onset of many of its adverse effects, and several studies in animal models have shown that such effects are observed after exposure to low doses (Vandenbreg et al. 2009). Brominated BPA analogs are not as estrogenic as BPA, and the potency of brominated-BPAs as ER agonists decreases as the number of bromine atoms increases (Merts et al. 2001). Conversely, the...
estrogenic activity of chlorinated congeners could be similar to or higher than that of BPA (Mutou et al. 2006; Takemura et al. 2005). Similarly, both TBBPA and TCBPA interact with and disrupt thyroid hormone receptor signaling (Kitamura et al. 2002). Recently, Somm et al. (2009) showed that perinatal exposure to BPA altered early adipogenesis in the rat, which is mediated by peroxisome proliferator-activated receptor γ (PPARγ), a nuclear hormone receptor whose dysregulation is involved in the onset of diabetes and obesity (Swendenborg et al. 2009). This suggests that BPA and its derivatives may also interact with this receptor. In the present study, we examined the capacity of BPA and halogenated BPA derivatives to interact with and perturb signaling by ERα, ERβ, PPARα, PPARδ, and PPARγ. We provide the first experimental evidence that flame retardants TBBPA and TCBPA are ligands and partial agonists of human PPARγ and also activate the corresponding zebrafish and Xenopus receptors. Our findings indicate that these compounds should certainly be evaluated as EDCs with possible deleterious effects on humans and wildlife.

**Material and Methods**

**Chemicals.** We purchased E2, perfluoro-octanesulfonic acid (PFOS), perfluoro-octanoic acid (PFOA), BPA, and TBBPA [2,2-bis(3,5-dibromo-4-hydroxyphenyl)propane] from Sigma-Aldrich (Saint-Quentin Fallavier, France); TCBPA [2,2-bis(3,5-dichloro-4-hydroxyphenyl)propane] from TCI Europe (Zwijndrecht, Belgium); and rosiglitazone from Interchim (Montluçon, France). Mono-2-ethylhexyl phthalate (MEHP) was a gift from M.C. Chagnon (AgroSup Dijon, Dijon, France). [3H]-Rosiglitazone (2,000 GBq/mmol) was purchased from PerkinElmer (Courtaboeuf, France). We obtained materials for cell culture from Invitrogen (Cergy-Pontoise, France) and luciferin from Promega (Charbonnieres, France). 3-MonobromoBPA, 3,3’-dibromoBPA, and 3,3’,5-tribromoBPA were synthesized from BPA. Brominated-BPA analogs were individually isolated and purified using HPLC and a Gilson 202 fraction collector (Gilson France, Villiers-le-bel, France) as described previously (Zalko et al. 2006). We evaluated the purity of all brominated analogs by ultraviolet HPLC, electrospray ionization mass spectrometry, and nuclear magnetic resonance (> 99.8%).

**Transient transfection experiments.** We monitored human (h), zebrafish, and Xenopus (x) PPARγ activity on (GAL4RE)2-β-globulin-luciferase and (PPRE)2-TK-luciferase reporter constructs. P5G5-GAL4-PPARγ-puro, pPS5-GAL4-puro, (GAL4RE)2-β-glob-luciferase, (PPRE)2-TK-luciferase were tested previously (le Maire et al. 2009). P5G5-xPPARγ was a gift from W. Wahl (University of Lausanne, Lausanne, Switzerland). Zebrafish PPARγ ligand-binding domain (LBD) was synthesized by Eurofins MWG Operon (Les Ulis, France) and cloned between BamHI and Xhol restriction sites in pSG5-GAL4-puro. Transient transfection and luciferase assays were performed as previously described (le Maire et al. 2009).

**Reporter cell lines and stable gene expression assay.** Generation of HGELN, HGELN-ERα, HGELN-ERβ, HGELN-GAL-PPARγ, HGELN-GAL-PPARδ, and HGELN-GAL-PPARγ reporter cell lines was performed as previously described (Escanède et al. 2006; le Maire et al. 2009). Briefly, reporter cells were seeded at a density of 20,000 cells/well in 96-well white opaque tissue culture plates and maintained in phenol-red-free Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% dextran-coated, charcoal-treated fetal calf serum. Twenty-four hours later, culture medium was replaced with DMEM containing tested compounds. We performed assays in the absence of serum to avoid ligand capture by serum proteins. Sixteen hours after exposure, we replaced media with media containing 0.3 mM luciferin. Luminescence was measured in intact living cells for 2 sec in a Microbeta Wallac luminometer (PerkinElmer).

**NIH3T3-L1 differentiation.** Two-day post-confluent 3T3L1 preadipocytes (a gift from L. Fajas; Institut de Génétique Moléculaire, Montpellier, France) were induced to differentiate by 2-day treatment with a differentiation mixture (10 μg/mL insulin, 1 μM dexamethasone, 0.5 mM isobutylmethylxanthine) followed by 8-day treatment with 10 μg/mL insulin and PPARγ ligands. The medium was replaced every 48 hr. After differentiation, cells were stained with Oil Red O for morphological analyses, or RNA was extracted from the cells using the RNeasy RNA isolation kit (Qiagen, Courtaboeuf, France). For RNA extractions, four independent cultures were performed per condition. Reverse transcription was performed with random hexamers on 1 μg total RNA using SuperScript II reverse transcriptase (Invitrogen), and the reaction was diluted 100 times for amplification. Real-time polymerase chain reaction (PCR) quantification was then performed using SYBR Green technology (LightCycler; Roche Diagnostics, Meylan, France). Results were normalized to two housekeeping genes (18S and 36B4) and quantified using qBase (Roche Diagnostics).

**PPARγ expression and purification.** DNA encoding the LBD of human PPARγ (amino acids Glu196–Try477) was amplified by PCR and cloned into the expression vector pET15b. The plasmid PPARγ-LBD (Glu196–Try477–pET15b) was transformed into E. coli Bl21(DE3) cells (Invitrogen). The PPARγ LBD was expressed and purified as previously described for retinoid X receptor (RXXR) LBD (Nahoum et al. 2007). Prior to crystallization trials, the purified PPARγ LBD was concentrated to 8.5 mg/mL in a buffer containing 20 mM Tris-HCl, pH 8.5, 250 mM NaCl, 5 mM dithiothreitol, and 1 mM EDTA.

**Crystalization.** Crystals were obtained by vapor diffusion in hanging drops at 293 K. For crystals of unliganded (apo) PPARγ, 1 μL protein solution was mixed with 1 μL well solution containing 1 M trisodium citrate, pH 7.5, 100 mM Hepes, pH 7.5, and 3% 1,2-propanediol. Crystals appeared after 1 day and grew to about 200 μm within a few days. TCBPA was soaked into a PPARγ apo-crystal by adding 0.5 μL TCBPA at a concentration of 1 mM suspended in well solution directly to the crystal drop. The crystals were soaked for 4 days. For co-crystals of PPARγ in complex with TBBPA, 1 μL protein solution was mixed with 1 μL well solution containing 1 M trisodium citrate, 100 mM HEPES, pH 7.5, 3.5% 1,2-propanediol, and 0.2 mM TBBPA ligand. Crystals showed an increase of 1.2% of protein/ligand in the drop. Crystals appeared after 1 day and grew to about 200 μm within a few days. Crystals were transferred to a cryoprotectant (well solution containing 20% glycerol and the corresponding ligand at a concentration of 1 mM) and frozen in liquid nitrogen.

**Crystallographic data collection, processing, and structure refinement.** We collected diffraction data at the ID14-1 beamline at 2.55 Å and 2.70 Å resolution for TBBPA-PPARγ and TCBPA-PPARγ complexes, respectively, using an ADSC Quantum Q210 CCD detector at the European Synchrotron Radiation facility (ESRF, Grenoble, France). Diffraction data were processed using MOSFLM (Leslie 2006) and scaled with SCALA from the CCP4 program suite (Collaborative Computational Project 1994). Structures were solved by using the previously reported structure ZVVT (Waku et al. 2009) from which the ligand was omitted. Initial Fo–Fc difference maps showed significant signals for the ligand, which could be fitted accurately into the electron density.
The structures were modeled with COOT (Emsley and Cowtan 2004) and refined with phenix.refine from the PHENIX program suite (Afonine et al. 2005).

### Results

**Halogenated BPA derivatives activate human ERα, ERβ, and PPARγ.** We monitored the agonistic potential of BPA and halogenated derivatives using stably transfected HGELN-ERα, -ERβ, -PPARα, -PPARδ, and -PPARγ cell lines, allowing for a comparison of the effect of compounds on human ER and PPAR subtypes in a similar cellular context. All compounds were first tested on the HGELN parental cell line containing only the reporter gene. We observed some toxicity at ligand concentrations of ≥ 10 μM but no unspecific modulation of luciferase expression (data not shown). We then characterized the activity of BPA, TCBPA, and TBBPA on HGELN-ER cell lines. As shown in Figure 2A and B, despite a reduced affinity relative to E2, BPA exerted an almost full agonistic activity toward both ERα and ERβ. In contrast, TBBPA had little effect on either ER, whereas TCBPA partially activated both receptor subtypes with a slight preference for ERβ. Similar experiments carried out using HGELN-PPAR cells demonstrated that none of the compounds tested notably affected PPARα or PPARδ activity (data not shown). In contrast, both TBBPA and TCBBPA were capable of partially activating PPARγ, despite being approximately 100-fold less potent than the reference pharmaceutical compound rosiglitazone (Figure 2C). The parent compound BPA failed to activate PPARγ. The occurrence of lower-brominated BPA analogs in the environment prompted us to measure their activity in HGELN-ER cell lines and HGELN-PPARγ cells (Figure 2D–F). Figure 2D shows that all brominated BPA congeners were partial ERα agonists with graded activities. BPA, monoBBPA, and diBBPA displayed the highest transactivation efficiency followed by triBBPA, whereas TBBPA had almost no activity in the HGELN-ERα cells. These compounds were also tested in the HGELN-ERβ cell line, providing a similar partial activity and ranking order of estrogenic potency (Figure 2E). MonoBBPA and diBBPA, the brominated analogs characterized by the highest estrogenic potency but the lowest molecular weight, exhibited a slight ERβ selectivity. Interestingly, when assayed in HGELN-PPARγ cells, the halogenated compounds ranked in the reverse order, with triBBPA and TBBPA showing the highest potency to induce luciferase gene expression, followed by diBBPA and monoBBPA (Figure 2F). Finally, we compared TBBPA and TCBPA with the well-known environmental PPARγ ligands MEHP (Feige et al. 2007), PFOS, and PFOA (Takacs and Abbott 2007) [see Supplemental Material, Figure 1 (http://dx.doi.org/10.1289/ehp.1003328)]. As shown in Figure 2G, the halogenated BPs triggered PPARγ activation at 10- to 100-fold lower concentrations than the other candidate PPARγ disruptors.

**Binding activity of TBBPA and TCBPA to human PPARγ receptor.** To further characterize the interaction between human PPARγ and halogenated BPA derivatives, we performed whole-cell competitive binding assays using HGELN-PPARγ cells. TBBPA and TCBPA competitively inhibited the binding of [3H]-rosiglitazone to PPARγ (Figure 3). The half maximal inhibitory concentration (IC50)
values for rosiglitazone, TBBPA, and TCBPA were 12.0 nM, 0.7 μM, and 6.0 μM, respectively. Together with transactivation assays (Figure 2C,F,G), these data demonstrate that TBBPA and TCBPA bind to human PPARγ and activate the receptor at concentrations in the micromolar range.

Halogenated BPA promotes adipocyte differentiation through PPARγ. Having shown that halogenated BPA is PPARγ ligands, we investigated the action of TBBPA and TCBPA on endogenous genes by studying their ability to induce adipogenesis, a well-characterized PPARγ-regulated function. As we expected, treatment of 3T3L1 preadipocytes with the full PPARγ agonist rosiglitazone strongly induced adipogenesis, as evidenced by Oil Red O staining, whereas the PPARγ antagonist CD5477 (le Maire et al. 2009) did not induce adipocyte differentiation (Figure 4A). TCBPA and TBBPA at 10 μM also induced adipogenesis, whereas co-treatment with CD5477 inhibited the adipogenic action of TBBPA, indicating that halogenated BPA activated zebrafish PPARγ, whereas MEHP was completely inactive. In contrast, all compounds, including rosiglitazone, activated Xenopus PPARγ. Together, our data indicate that halogenated BPA can disrupt the activity of PPARγ from different species.

Structural analysis of the TBBPA- and TCBPA-PPARγ complexes. Finally, we solved the crystal structures of TBBPA and TCBPA bound to the PPARγ LBD to reveal the mechanism by which these compounds, which are structurally unrelated to known PPARγ ligands, bind to and activate this receptor [see Supplemental Material, Figure 3B (http://dx.doi.org/10.1289/ehp.1003328)]. As exemplified by the PPARγ–TBBPA complex (Figure 6A), the structures reveal the canonical tertiary fold of agonist-bound nuclear hormone receptor LBDs (Bourguet et al. 2000). The TBBPA and TCBPA complex structures are indistinguishable, with a root mean square deviation (RMSD) value of 0.29 Å for superimposed alpha carbons (see Supplemental Material, Figure 2) and nearly identical to that of PPARγ in complex with the agonist rosiglitazone (Noëte et al. 1998), with an RMSD value of 0.62 Å (Figure 6B). Omission of F from difference maps for the TBBPA and TCBPA structures revealed clear density for the ligands that could be positioned unambiguously into the PPARγ ligand-binding pocket (LBP) (see Supplemental Material, Figure 3B). PPARγ displays a large LBP that extends from the C-terminal helix H12 to the β-sheet S1/S2 so that halogenated BPA occupies a small portion of the LBP (Figure 6A). Whereas rosiglitazone occupies a region of the LBP spanning H11/H12 to the β-sheet S1/S2, TBBPA and TCBPA occupy only the region between H3 and the β-sheet S1/S2, with a loop (Aβ) nested between H3 and the β-sheet (Figure 6B,C). In contrast with rosiglitazone, a consequence of the smaller size of halogenated BPA ligands, they do not interact directly with H12 (Figure 6B,C). A close look at the LBP shows that the phenol groups of the BPA derivatives are involved in hydrogen bonds. The hydroxyl
group from cycle A (Figure 6D) interacts with the main chain nitrogen atom of Ser342 (β-sheet S1/S2), whereas the second one (cycle B) is hydrogen-bonded to Ser289 in H3 and Tyr473 from H12 through a water-mediated hydrogen bond network (Figure 6E). TBBPA and TCBPA contain four halogen atoms that contribute to ligand binding through van der Waals interactions (Figure 6D,E). Additional interactions involving the ligand backbone were also observed (Figure 6F). Interestingly, comparison of human, mouse, and zebrafish PPARγ sequences reveals several residue differences, which could explain the differential ligand specificity of the various species (see Supplemental Material, Figure 3A). In particular, the replacement of human PPARγ Gly284 and Cys285 by serine and tyrosine residues in zebrafish PPARγ provides a rationale for the weak binding affinity of rosiglitazone for this receptor compared with that observed for the human homolog (see Supplemental Material, Figure 3B). In contrast, the different binding mode of halogenated compounds allows both human PPARγ and zebrafish PPARγ to accommodate TBBPA and TCBPA (see Supplemental Material, Figure 3B).

**Discussion**

Mounting data indicating the presence of halogenated bisphenols in environmental and human samples clearly suggest that these compounds should be considered an emerging class of contaminants whose cellular targets and effects require better understanding (Cariou et al. 2008; de Wit et al. 2010; Fernandez et al. 2007; Guerra et al. 2010). Brominated BPA analogs result mainly from the extensive use of TBBPA as a flame retardant, whereas a growing body of evidence suggests that chlorinated BPA analogs arise from the abiotic chlorination of BPA residues (Fukazawa et al. 2001). In the present study, we investigated the possible role of BPA and halogenated BPA derivatives as environmental ligands for ERs and PPARs.

We used HeLa cells, which are characterized by low intrinsic metabolic capabilities, to examine ER and PPAR activities to minimize metabolic biotransformations of tested compounds, which potentially can lead to a misinterpretation of *in vitro* results. Toxicity of halogenated BPA derivatives toward HeLa cell lines was observed at concentrations >10 μM, which is fully consistent with previous reports showing that both TBBPA and TCBPA are more toxic than BPA (Nakagawa et al. 2007). For brominated analogs, the ranking order of estrogenic potency in HELN-ERβ and HELN-ERα cell lines was monoBBPA > diBBPA > triBBPA, whereas TBBPA showed no estrogenic activity at all. In a similar study using T47D breast cancer cells, Meerts et al. (2001) reported similar findings. Interestingly, in HGELN-PPARγ cells, the ability of BPA analogs to activate PPARγ was reversed, with TBBPA = triBBPA > diBBPA >> monoBBPA. The activity of TCBPA was similar to that of TBBPA.

Full agonists of PPARγ (e.g., rosiglitazone) have been reported to fully activate their cognate receptor by directly interacting with and stabilizing helix H12, whereas compounds that do not directly contact H12 behave as weak or partial agonists by stabilizing other regions of the LBD, including H3 and the β-sheet S1/S2 (Bruning et al. 2007; Kallenberger et al. 2003). Both the functional and structural studies reported here support this model of partial PPARγ agonism by TBBPA and TCBPA. The rather weak affinity of halogenated BPAs for PPARγ compared with rosiglitazone can be explained by their smaller size and correspondingly fewer direct atomic contacts with the protein. Notably, whereas rosiglitazone is engaged in five hydrogen bonds with the protein, only two hydrogen bonds are observed between TBBPA/TCBPA and PPARγ (see Supplemental Material, Figure 4). The remaining contacts involve 89, 79, and 75 van der Waals interactions for

![Figure 5](http://dx.doi.org/10.1289/ehp.1003328). The remaining contacts involve 89, 79, and 75 van der Waals interactions for PPARγ ligands.

![Figure 6](http://dx.doi.org/10.1289/ehp.1003328). The remaining contacts involve 89, 79, and 75 van der Waals interactions for PPARγ ligands.
rosiglitazone, TBBPA, and TCBPA, respectively (with a distance cutoff of 4.20 Å). The combination of significantly smaller size and the loss of stabilizing interactions between the halogen atoms of the halogenated BPA derivatives and PPARγ most likely accounts for the absence of significant interaction between the parent compound BPA and this receptor. Conversely, whereas the large LBP of of PPARγ (Nolte et al. 1998) can readily accommodate the addition of bulky bromine or chlorine atoms, the much smaller LBP of the ERs cannot, thus providing an explanation for the differential pattern of interactions of halogenated BPAs with the two receptor types. It is noteworthy that some halogenated BPAs, including TCBPA and diBPA, can interact with both ERs and PPARγ. This dual activity could increase the toxicity of these compounds compared with BPA or TBBPA, which are ER- and PPARγ-selective ligands, respectively. The comparison of the adverse effects induced by the two types of compounds through in vivo experiments should provide information on whether the dual ER/PPAR halogenated-BPA ligands display a higher EDC potency on reproductive and metabolic functions than more selective congeners. Until now, several environmental (including MEHP, PFOS, PFOA, and organotins) have been found to interfere significantly with PPARγ signaling (Feige et al. 2007; Grün and Blumberg 2006; Grün et al. 2006; Takacs and Abbott 2007). In this regard, we recently reported that organotins potently activate RXR-PPAR heterodimers essentially through binding to the RXR subunit (Le Maire et al. 2009). Conversely, the functional and structural data presented here demonstrate that halogenated BPAs are capable of activating PPARγ via direct interactions characterized by binding affinities that are 10- to 100-times higher than other proposed PPARγ disruptors. The discovery of a novel chemical class of PPARγ activators strengthens the hypothesis that environmental ligands could be involved in the disruption of energy balance in humans and wildlife. As with other EDCs, perinatal exposure could play a critical role. According to Cariou et al. (2008), significant levels of TBBPA can be found in human cord blood (200 pg/g fresh weight) and maternal milk (0.1–37.4 ng/g lipid weight), demonstrating both prenatal and postnatal exposure in a large fraction of the population. Furthermore, as other XRs (the main active form of PPARγ is the RXR/PPARγ heterodimer) and PPARγ activators are also present in the environment, additive (acting only through PPARγ) and synergistic (acting through both RXR and PPARγ) effects could occur and further increase the risk of metabolic diseases. In this regard, the “cocktail effect” resulting from a concomitant exposure to organotins and halogenated-BPAs could be particularly deleterious.

**References**


